Gilead Sciences | GILD - Despesas De Vendas E Administração

Preço das Ações
130.40
Mudança Diária
-3.24 -2.42%
Mensal
-5.68%
Anual
26.39%
Q2 Previsão
127.61




Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.89B 325M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 390.41M 61.33M 2025-12
J&J USD 6.03B 719M 2026-03
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12